Cargando…

Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience

INTRODUCTION: Daptomycin, a rapid concentration-dependent bactericidal antibiotic, is approved at a dose of 4 mg/kg/day for the treatment of complicated skin and soft tissue infections (cSSTI) and at a dose of 6 mg/kg/day for the treatment of Staphylococcus aureus right-sided infective endocarditis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seaton, R. Andrew, Menichetti, Francesco, Dalekos, Georgios, Beiras-Fernandez, Andres, Nacinovich, Francisco, Pathan, Rashidkhan, Hamed, Kamal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679787/ https://www.ncbi.nlm.nih.gov/pubmed/26610384 http://dx.doi.org/10.1007/s12325-015-0267-4

Ejemplares similares

Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin(®) Outcomes Registry and Experience (EU-CORE)
por: Guleri, Achyut, et al.
Publicado: (2015)

Real-World Treatment of Complicated Skin and Soft Tissue Infections with Daptomycin: Results from a Large European Registry (EU-CORE)
por: Cogo, Alberto, et al.
Publicado: (2015)

Daptomycin for Gram-positive Infections in Patients with Neutropenia: Clinical Experience from a European Outcomes Registry
por: Keil, Felix, et al.
Publicado: (2015)

A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections
por: Shoemaker, D Matthew, et al.
Publicado: (2006)

Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry
por: Malizos, K., et al.
Publicado: (2015)

Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE
por: Seaton, R. Andrew, et al.
Publicado: (2016)

Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents
por: Syriopoulou, Vassiliki, et al.
Publicado: (2016)

Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry
por: Gonzalez-Ruiz, Armando, et al.
Publicado: (2015)

Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database
por: Seaton, R. Andrew, et al.
Publicado: (2013)

Clinical experience with daptomycin in Europe: the first 2.5 years
por: Gonzalez-Ruiz, Armando, et al.
Publicado: (2011)

Real-World Treatment of Enterococcal Infections with Daptomycin: Insights from a Large European Registry (EU-CORE)
por: Lübbert, Christoph, et al.
Publicado: (2015)

Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections
por: Gonzalez-Ruiz, Armando, et al.
Publicado: (2016)

Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens
por: Beiras-Fernandez, Andres, et al.
Publicado: (2010)

Daptomycin as supportive treatment option in patients developing mediastinitis after open cardiac surgery
por: Weis, Florian, et al.
Publicado: (2012)

Daptomycin for the treatment of major gram-positive infections after cardiac surgery
por: Kornberger, A., et al.
Publicado: (2016)

Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin
por: White, Beth, et al.
Publicado: (2011)

A case of endocarditis with cerebral embolism successfully treated with daptomycin
por: Doria, Roberta, et al.
Publicado: (2011)

Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry
por: Martone, W J, et al.
Publicado: (2008)

High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: Case report
por: Chen, Liang-Yu, et al.
Publicado: (2011)

Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy
por: Xu, Xiaoying, et al.
Publicado: (2016)

Safety of high-dose daptomycin in patients with severe renal impairment
por: Tai, Chih-Hsun, et al.
Publicado: (2018)

Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin
por: Kebriaei, Razieh, et al.
Publicado: (2023)

Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections
por: Timerman, Artur, et al.
Publicado: (2013)

Daptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible enterococcus
por: Storm, Jeremy C, et al.
Publicado: (2012)

Daptomycin-Nonsusceptible Staphylococcus aureus: The Role of Combination Therapy with Daptomycin and Gentamicin
por: Jiang, Jhih-Hang, et al.
Publicado: (2015)

Chemoenzymatic synthesis of daptomycin analogs active against daptomycin-resistant strains
por: Scull, Erin M., et al.
Publicado: (2020)

Should High-dose Daptomycin be an Alternative Treatment Regimen for Enterococcal Endocarditis?
por: Peghin, Maddalena, et al.
Publicado: (2019)

Emergence of a daptomycin-non-susceptible Enterococcus faecium strain that encodes mutations in DNA repair genes after high-dose daptomycin therapy
por: Matono, Takashi, et al.
Publicado: (2016)

Acute Eosinophilic Pneumonia Secondary to Daptomycin
por: Somoza-Cano, Francisco J, et al.
Publicado: (2021)

759. High-Dose Daptomycin Is Well Tolerated via 2-Minute Infusion
por: Gill, Christian Mark, et al.
Publicado: (2019)

Genomic and Long-Term Transcriptomic Imprints Related to the Daptomycin Mechanism of Action Occurring in Daptomycin- and Methicillin-Resistant Staphylococcus aureus Under Daptomycin Exposure
por: Cafiso, Viviana, et al.
Publicado: (2020)

Acute Angioedema Triggered by Daptomycin
por: Gisler, Valentin, et al.
Publicado: (2016)

1403. Daptomycin Combined with Low Dose Ceftriaxone Prevents the Emergence of Daptomycin Resistance against Streptococcus mitis-oralis Group in an In vitro Model of Simulated Endocardial Vegetations (SEVs)
por: Kebriaei, Razieh, et al.
Publicado: (2018)

Fitness Cost of Daptomycin-Resistant Staphylococcus aureus Obtained from in Vitro Daptomycin Selection Pressure
por: Li, Shuguang, et al.
Publicado: (2017)

1546. Efficacy of Daptomycin Combinations Against Daptomycin-Resistant Enterococcus faecium Differs by β-lactam
por: Kebriaei, Razieh, et al.
Publicado: (2019)

Daptomycin for the Treatment of Gram-Positive Periprosthetic Hip Infections: Can Daptomycin Prevent the Implant Removal?
por: Oe, Kenichi, et al.
Publicado: (2021)

Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection
por: Schaad, Heinz J, et al.
Publicado: (2006)

1084. Comparative Outcomes Among Patients Receiving Varying Daptomycin Dosing Regimens in Hemodialysis
por: Maxwell, Tyler, et al.
Publicado: (2021)

Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment
por: Ye, Lingling, et al.
Publicado: (2022)

A Pharmacovigilance Analysis of Daptomycin Use Based on CLSI Susceptible Dose-Dependent Category
por: Zhang, Ming M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f6plv1smi4lstkqiij3t96qj8d